1. Introduction

The pharmaceutical industry operates under stringent regulatory requirements to ensure that medicines are safe, effective, and consistently manufactured. The United States Food and Drug Administration (USFDA or FDA) oversees pharmaceutical manufacturing facilities through inspections, regulatory assessments, records reviews, and other compliance activities.

As global supply chains become more complex and manufacturing systems generate increasing amounts of electronic data, traditional approaches to identifying quality risks may need additional analytical support.

Risk-based inspections help regulators prioritize facilities and activities according to potential risks to patients and product quality. Artificial Intelligence, machine learning, predictive analytics, and automated data-analysis tools can also help pharmaceutical companies identify recurring quality problems and strengthen their internal audit programs.

However, risk-based inspection planning and AI-assisted inspection activities should not be confused. Risk-based inspection is an established regulatory approach, whereas the application of specific AI technologies to pharmaceutical inspection activities continues to evolve.

Understanding this distinction is important for QA, QC, Production, Engineering, Validation, and Regulatory Affairs professionals.

2. What Is a Risk-Based USFDA Inspection?

A risk-based inspection is an approach in which inspection priorities and resources are determined using relevant information about potential risks to product quality, patient safety, and regulatory compliance.

The FDA oversees a large number of domestic and foreign pharmaceutical manufacturing facilities. A risk-based approach helps the agency prioritize its inspection activities and determine where regulatory attention may be most beneficial.

Factors that may influence inspection planning include:

• Previous inspection history and compliance status.
• Product type and potential patient risk.
• Manufacturing complexity and process controls.
• Relevant complaints, recalls, and quality signals.
• Facility-specific compliance concerns.
• Available information from other regulatory authorities.
• Other information relevant to the safety, quality, and availability of medicines.

For example, a facility manufacturing sterile injectable products may have different inherent risks from a facility manufacturing conventional immediate-release tablets. The appropriate inspection scope depends on the facility, products, operations, and relevant risk factors.

A lower inspection priority does not exempt a facility from applicable current Good Manufacturing Practice (cGMP) requirements.

Official reference: FDA’s Risk-Based Approach to Inspections.

3. Factors Influencing Risk-Based Inspection Prioritization

Risk assessment helps identify facilities, quality systems, and manufacturing processes that may require closer examination.

The table represents general risk considerations. It is not an official FDA scoring model, and the FDA does not necessarily apply identical weights to these factors for every inspection.

4. Recent Developments in FDA Inspections

The FDA continues to explore ways to improve inspection coverage and make effective use of its inspectional resources.

In May 2026, the FDA announced a pilot program involving one-day inspectional assessments. These focused assessments were intended to complement standard inspections and support broader oversight of regulated facilities.

The agency described the use of risk-related information, recurring compliance themes, and discrepancies between registered and actual operations as factors that can help inform inspection targeting.

These assessments were not intended to replace standard inspections. Their scope and duration could be extended when significant concerns were identified.

What does this mean for pharmaceutical companies?

• Maintain inspection readiness throughout the year.
• Keep approved procedures and supporting records current.
• Ensure that quality investigations are complete and scientifically justified.
• Monitor recurring deviations and CAPA effectiveness.
• Maintain reliable electronic records and appropriate access controls.
• Ensure that actual operations are consistent with approved procedures and applicable regulatory commitments.

Official reference: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight.

5. What Is Artificial Intelligence in Pharmaceutical Audits?

Artificial Intelligence refers to technologies that perform tasks such as recognizing patterns, analyzing information, classifying records, generating summaries, and supporting predictions.

In pharmaceutical quality management, AI may be used alongside conventional statistical methods and automated workflows to support risk identification and internal audit preparation.

These technologies have different capabilities and limitations. Their suitability depends on the intended use, data quality, model performance, and level of human oversight.

6. Is the FDA Using AI Tools During Pharmaceutical Inspections?

This question requires a clear distinction between confirmed FDA initiatives and potential AI applications.

The FDA has publicly described risk-based inspection planning, remote regulatory assessments, records requests, and its 2026 one-day inspectional assessment pilot. These developments demonstrate the agency’s interest in using different approaches to improve regulatory oversight.

However, risk-based inspection planning does not automatically mean that the FDA uses generative AI to review every GMP document or determine every inspection finding. The use of a specific AI tool for a particular inspection activity should be confirmed through official documentation rather than assumed.

In January 2025, the FDA published draft guidance titled Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.

The draft guidance proposes a risk-based framework for assessing the credibility of AI models used to generate information supporting regulatory decisions about the safety, effectiveness, or quality of drug and biological products.

It should not be interpreted as confirmation that all FDA inspections are conducted using AI.

Three important distinctions

1. Established regulatory practice: Risk-based inspection prioritization and appropriate alternative oversight tools.
2. Published AI policy direction: A proposed framework for assessing AI model credibility in specified regulatory decision-making contexts.
3. Potential applications: AI-assisted document review, quality trend analysis, anomaly detection, and internal audit preparation.

Official reference: FDA Draft Guidance on AI for Regulatory Decision-Making.

7. Applications of AI in Pharmaceutical Audits

7.1 AI-assisted deviation analysis

Pharmaceutical companies may have hundreds or thousands of deviation records across manufacturing, packaging, engineering, QC, and QA.

AI-assisted text analysis can help group similar events and identify recurring themes, such as:

• Tablet weight variation.
• Compression-force excursions.
• Equipment breakdowns.
• Repeated line-clearance failures.
• Packaging defects.
• Incomplete investigations.

QA can use these patterns to prioritize internal reviews and investigate whether a systemic problem exists. AI-generated classifications should be checked against the original records before conclusions are made.

7.2 AI-assisted CAPA effectiveness monitoring

AI-assisted analytics may help identify recurring deviations linked to previously closed CAPAs, overdue actions, and similar failures across different departments.

For example, if a CAPA is closed after procedure revision and retraining but similar deviations continue, an analytical tool may flag the recurrence for QA review.

The quality team must determine whether the root cause was correctly identified, whether the action was adequate, and whether additional corrective or preventive measures are required.

7.3 AI-assisted audit-trail analysis

Electronic systems generate substantial volumes of data. Analytics may help identify patterns such as repeated record modifications, unusual sequences of system events, missing expected records, or repeated alarm overrides.

These patterns are potential investigation signals, not automatic proof of a data-integrity violation. QA and IT personnel should review the source data, metadata, audit trails, system configuration, and documented explanations before reaching a conclusion.

7.4 AI-assisted SOP and document review

AI tools can help compare controlled documents and identify potential inconsistencies, such as conflicting instructions, missing references, or outdated citations.

For example, a document-review tool may identify differences between a manufacturing SOP and a related training document.

Qualified personnel must review the findings and process any required revisions through the approved document-control system.

7.5 AI-assisted complaint trending

Market complaint text can be classified into categories such as broken tablets, damaged blister pockets, missing tablets, labeling defects, or packaging failures.

QA can compare complaint patterns with manufacturing deviations, packaging-line rejection data, batch-release information, supplier complaints, and existing CAPAs.

This analysis may help identify quality signals that are difficult to recognize when records are reviewed separately.

7.6 AI-assisted inspection document retrieval

During inspection preparation, QA teams often need to retrieve SOPs, batch records, validation reports, training records, investigations, and change controls.

A controlled document-assistance tool may help authorized employees locate relevant records more efficiently. For example, a search for process validation may identify an approved protocol, report, related deviations, and CPV reports.

All retrieved documents must be checked against the authoritative records in the approved document management or quality management system. AI-generated summaries must not replace original GMP records.

8. Practical Example: Combining Risk-Based Auditing With AI

Consider a pharmaceutical company manufacturing immediate-release tablets. During routine quality review, the company identifies an increase in deviations related to tablet weight variation, feeder performance, and compression-machine adjustments.

The company may use a risk-based internal audit approach to prioritize the compression process because recurring deviations could affect product quality.

An AI-assisted analytical tool may help identify related records across Production, Engineering, QA, and QC.

This example illustrates a potential internal use of AI-assisted analytics. It does not represent a confirmed FDA inspection workflow.

9. AI-assisted Risk Scoring for Internal Audits

Pharmaceutical companies may develop documented risk-scoring frameworks to determine which internal audits should receive priority.

AI may support the analysis of historical records and identify changes in relevant risk indicators.

A company should document its scoring method, justify the selected factors, and review the model periodically. Human oversight is essential, especially when the results influence audit scheduling or quality-system priorities.

An internal audit risk score is not equivalent to the FDA’s internal inspection-prioritization methods.

10. Data Integrity Risks When Using AI Tools

AI can create additional risks if the tool is poorly configured, trained on unsuitable data, or used without adequate controls.

10.1 Incorrect or fabricated outputs

Generative AI may produce inaccurate explanations, unsupported regulatory references, or conclusions that are not present in the source records.

10.2 Incomplete input data

If the model receives only selected records, it may overlook relevant evidence and generate misleading conclusions.

10.3 Confidentiality and privacy

Uploading batch records, confidential manufacturing information, investigation reports, or personal information to an unapproved external AI service may create confidentiality and compliance risks.

10.4 Model bias

A model trained on historical data may reproduce existing weaknesses or fail to recognize new types of quality events.

10.5 Poor traceability

If an organization cannot identify the input data, model version, processing steps, output, and reviewer decisions, reconstructing how a conclusion was reached may become difficult.

10.6 Automation bias

Employees may accept AI-generated recommendations without sufficiently challenging their accuracy or scientific basis.

To manage these risks, companies should establish permitted uses, maintain appropriate access controls, document important outputs, assess model performance, and require qualified personnel to review consequential conclusions.

11. Validation and Governance of AI Tools

Before introducing AI into a GMP-related workflow, the organization should evaluate the intended use and potential impact on product quality, patient safety, and record reliability.

The level of assurance should be proportionate to the application’s risk.

1. Define intended use: Document the activity the tool is designed to support and its limitations.
2. Assess data quality: Verify that source records are appropriate, complete, and reliable.
3. Evaluate risks: Consider the consequences of inaccurate, incomplete, or misleading outputs.
4. Test performance: Establish suitable acceptance criteria and evaluate performance using representative data.
5. Control access: Establish appropriate access, confidentiality, and security requirements.
6. Maintain traceability: Document important inputs, outputs, reviews, and decisions.
7. Define human oversight: Specify who reviews and approves the output.
8. Monitor performance: Evaluate errors, missed signals, and unexpected behavior.
9. Control changes: Assess updates to software, configuration, models, and intended use.
10. Review periodically: Confirm that the tool remains suitable for its approved purpose.

Organizations should evaluate applicable requirements for computerized systems, electronic records, electronic signatures, and data integrity. The appropriate validation and assurance approach depends on the intended use and applicable regulations.

An AI tool used to classify complaint text may have a different risk profile from a system used to support batch-release decisions. The level of control should reflect that difference.

12. Can AI Replace Pharmaceutical Auditors or FDA Investigators?

No. AI can support selected analytical and administrative activities, but it cannot independently establish complete GMP compliance.

Human expertise remains essential for:

• Evaluating scientific and technical evidence.
• Interviewing personnel and understanding actual manufacturing practices.
• Assessing potential patient and product risks.
• Determining whether an investigation is scientifically justified.
• Evaluating CAPA adequacy and effectiveness.
• Interpreting applicable regulations and guidance.
• Making decisions within assigned quality or regulatory responsibilities.

AI may identify a pattern that deserves attention, but the auditor or investigator must evaluate the evidence and determine its significance.

Similarly, an AI-generated compliance score should not be treated as proof that a facility is inspection-ready.

13. Implementation Roadmap for Pharmaceutical QA Teams

A phased implementation is generally more practical than deploying AI across every quality process at once.

Suitable pilot projects may include deviation classification, CAPA recurrence analysis, complaint categorization, internal audit scheduling, or controlled document retrieval.

Each project should have a defined purpose, measurable success criteria, and appropriate controls.

14. Performance Indicators for AI-Assisted Auditing

The value of AI should be evaluated using measurable indicators rather than assumptions about efficiency.

Metrics should be defined before implementation and interpreted according to the tool’s intended use. Faster review does not necessarily mean better quality if critical risks are missed.

15. Future Outlook: Risk-Based Inspections and AI

Risk-based inspection planning and AI-assisted analytics are likely to remain important topics as pharmaceutical companies and regulators work with increasingly large volumes of manufacturing and quality data.

Potential future applications include more advanced anomaly detection, improved analysis of recurring quality failures, automated document classification, and more efficient retrieval of regulatory records.

However, organizations should distinguish between technological potential and confirmed regulatory practice. A new AI capability does not automatically become an FDA requirement, and AI adoption does not guarantee a favorable inspection outcome.

The most effective approach combines reliable data, sound scientific methods, trained personnel, a mature quality management system, and carefully controlled digital tools.

16. Conclusion

Risk-based USFDA inspections help focus regulatory attention on facilities, products, and processes that may present greater risks to patient safety and product quality.

Recent FDA developments, including the 2026 one-day inspectional assessment pilot, demonstrate continued interest in targeted and efficient oversight.

AI-assisted analytics can complement pharmaceutical quality management by helping companies identify recurring deviations, monitor CAPA effectiveness, review quality trends, and prepare for internal audits.

Nevertheless, AI must be implemented with appropriate controls. Its outputs require verification, its limitations must be understood, and consequential quality decisions must remain within established authorized processes.

For pharmaceutical QA leaders, the priority is not simply to adopt AI. It is to use technology responsibly to strengthen risk management, improve data reliability, and prevent quality failures.

The future of pharmaceutical inspection readiness lies in combining risk-based thinking, reliable data, responsible AI, and a strong quality culture.

17. References and Further Reading

1. FDA: Risk-Based Approach to Inspections
2. FDA: One-Day Inspectional Assessments, May 2026
3. FDA: Investing in FDA’s Inspectional Enterprise
4. FDA: AI for Regulatory Decision-Making, Draft Guidance, January 2025
5. FDA: Pharmaceutical Inspections and Compliance
6. FDA: Types of Inspections